Quantcast
Home > Quotes > PRNB
PRNB

Principia Biopharma Inc. Common Stock (PRNB) Quote & Summary Data

$32
*  
0.35
1.11%
Get PRNB Alerts
*Delayed - data as of May 21, 2019  -  Find a broker to begin trading PRNB now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
45
Today's High / Low
$ 32.77 / $ 31.4469
Share Volume
310,420
50 Day Avg. Daily Volume
132,984
Previous Close
$ 31.65
52 Week High / Low
$ 38.3399 / $ 22
Market Cap
763,733,792
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
310,420
50 Day Avg. Daily Volume:
132,984

Trading Range

The current last sale of $32 is 45.45% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 32.77 $ 38.3399
 Low: $ 31.4469 $ 22

Company Description (as filed with the SEC)

We are a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Our proprietary Tailored Covalency┬« platform enables us to design and develop reversible covalent and irreversible covalent, small molecule inhibitors with potencies and selectivities that we believe will rival those of injectable biologics, but with the convenience of a pill. We have produced three new drug candidates from our platform, resulting in four clinical programs. In November 2018, we initiated a pivotal Phase 3 trial of PRN1008, a wholly owned Bruton's Tyrosine Kinase, or BTK, inhibitor for the treatment of pemphigus (pemphigus vulgaris (PV) and pemphigus foliaceus (PF)). We retain full, worldwide rights to PRN1008, PRN1371 and our oral immunoproteasome inhibitor program, and have established an ongoing collaboration with Sanofi for PRN2246/SAR442168.  ... More ...  



Risk Grade

Where does PRNB fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 31.95
Open Date:
May 21, 2019
Close Price:
$ 32
Close Date:
May 21, 2019


Consensus Recommendation

Analyst Info